uniQure N.V.
QURE Healthcare Biotechnology
uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.
Follow QURE
uniQure N.V. (QURE) EV/Sales
As of 16 October 2026, uniQure N.V. (QURE) trades at a EV/Sales of 36.8×. Over the past ten years it has ranged from −17.6× (March 2024) to 432× (June 2020); the current reading is higher than 60% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 50.4× | 148.00% |
| FY2024 | 20.3× | — |
| FY2023 | −11.2× | — |
| FY2022 | 7.3× | 656.41% |
| FY2021 | 1.0× | (97.42%) |
| FY2020 | 37.5× | (89.23%) |
| FY2019 | 348× | 369.57% |
| FY2018 | 74.1× | 139.51% |
| FY2017 | 30.9× | 2,137.03% |
| FY2016 | 1.4× | (91.07%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 123× | 347.85% |
| Mar 2026 | 27.5× | (45.45%) |
| Dec 2025 | 50.4× | (71.46%) |
| Sep 2025 | 177× | 466.23% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MAZE Maze Therapeutics, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | 2.5× |
| KRSA Korsana Biosciences, Inc. compare | 8.8× |
| NTLA Intellia Therapeutics, Inc. compare | 18.3× |
| OCUL Ocular Therapeutix, Inc. compare | 19.6× |
| QURE uniQure N.V. | 36.8× |
| STOK Stoke Therapeutics, Inc. compare | 47.2× |
| ABSI Absci Corporation compare | 704× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)